Compare Heron Therapeutics Inc (HRTX) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $214.27 (market cap $39.15B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 575.7× Heron Therapeutics Inc's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days on average.
| HRTX | TTWO | |
|---|---|---|
Market Cap | $68.01M | $39.15B |
Volume | 1,891,941 | 2,708,429 |
Sector | Health | Technology |
52-Week High | $1.49 | $262.29 |
52-Week Low | $0.27 | $189.69 |
Typical Hold Time | 35 Days | 111 Days |
Enterprise Value | $174.75M | $40.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Take-Two Interactive (TTWO) trades at $213.88, up 4.84% with bullish technical signals and strong analyst support. The company shows mixed fundamentals with revenue growth to $5.63B but negative net income of -$4.48B, though recent earnings beats and the upcoming GTA VI launch provide optimism. Technical indicators show the stock trading near resistance at $215 with RSI suggesting potential overbought conditions.
The outlook remains positive driven by GTA VI's November launch, with analysts projecting 37% upside to $292.30 consensus target. Key risks include persistent profitability challenges, high debt levels, and execution pressure on major game releases. Institutional ownership trends show continued confidence despite recent financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
